Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program

The article presents preliminary results of a subanalysis of PREVOSHODSTVO (SUPERIORITY) phase IV study. Aim of this subanalysis was to assess efficacy and tolerability of a fixed-dose perindopril/amlodipine combination (FDPAC) in patients with arterial hypertension (AP) uncontrolled on previous treatment with angiotensin receptor blockers (ARBs). Material and methods. We included in this analysis 125 patients (70.4% women, mean age 57.2 +/- 10.0 years), final analysis of efficacy was performed on 124 patients. Before inclusion in the study 47 patients received ARB either as monotherapy (n=47), or components of free-dose (n=49) and fixed-dose (n=28) dual combinations with other antihypertensive drugs. Dose. of FDPAC was determined by physician. Duration of observation period was 24 weeks. Results. After 2 weeks significant reduction of blood pressure (BP) (from 159.9 +/- 8.8/93.8 +/- 6.8 to 143.9 +/- 10.7/86.4 +/- 6.5 mm Hg, p < 0.001) was noted. At final visit mean BP was 125.1 +/- 7.1/78.1 +/- 4.7 mm Hg. Number of patients with target BP (< 140/90 mm Hg) was 24, 75 and 97% after 1, 3, and 6 months, respectively. Visit-to-visit systolic BP variability by the end of the observation period decreased to 3.8 +/- 2.3 mm Hg. Conclusion. In patients, whose hypertension was not controlled by treatment with ARBs the fixed-dose combination of perindopril/amlodipine provided high percentage of achievement of target BP and reduction of long-term BP variability.